James Cassidy's most recent trade in SpringWorks Therapeutics Inc was a trade of 50,615 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 10, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 50,615 | 50,615 | - | - | Stock Option (Right to Buy) | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 17,323 | 81,731 (0%) | 0% | 0 | Common Stock | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.19 per share. | 04 Jan 2025 | 4,325 | 69,531 (0%) | 0% | 38.2 | 165,172 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.19 per share. | 04 Jan 2025 | 3,465 | 66,066 (0%) | 0% | 38.2 | 132,328 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.86 per share. | 04 Jan 2025 | 1,658 | 64,408 (0%) | 0% | 38.9 | 64,430 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.71 per share. | 30 Aug 2024 | 1,969 | 73,856 (0%) | 0% | 41.7 | 82,127 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.53 per share. | 01 Jul 2024 | 591 | 75,825 (0%) | 0% | 38.5 | 22,771 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 28,208 | 79,866 (0%) | 0% | 0 | Common Stock | |
SpringWorks Therapeutics Inc | Cassidy James | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.96 per share. | 04 Jan 2024 | 2,357 | 77,509 (0%) | 0% | 38.0 | 89,472 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.53 per share. | 04 Jan 2024 | 1,093 | 76,416 (0%) | 0% | 41.5 | 45,392 | Common Stock |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 5,720 | 52,950 (0%) | 0% | - | Common Stock | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 22,663 | 48,493 (0%) | 0% | - | Common Stock | |
SpringWorks Therapeutics Inc | James Cassidy | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.52 per share. | 05 Jan 2023 | 1,263 | 47,230 (0%) | 0% | 27.5 | 34,758 | Common Stock |